Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Lodovico Terzi-di-Bergamo et al.|Blood|2015Cited by 215
Drug resistance and BCR‐ABL kinase domain mutations in Philadelphia chromosome–positive acute lymphoblastic leukemia from the imatinib to the second‐generation tyrosine kinase inhibitor era: The main changes are in the type of mutations, but not in the frequency of mutation involvementSimona Soverini, Giovanni Martinelli, Mario Luppi et al.|Cancer|2013Cited by 143
Additional lesions identified by genomic microarrays are associated with an inferior outcome in low‐risk chronic lymphocytic leukaemia patientsGian Matteo Rigolin, Antonio Cuneo, Alice Traversa et al.|British Journal of Haematology|2023Cited by 2